News
A Phase III randomized trial published in JAMA Network Open found no significant difference in symptom improvement between ...
JNJ-1900 (NBTXR3), a novel, potentially first-in-class oncology therapy, demonstrated a median overall survival of 23 months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback